KALVISTA PHARMACEUTICALS LIMITED
Get an alert when KALVISTA PHARMACEUTICALS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£61M
+516.4% vs 2024
Net assets
-£31M
-2,999.5% vs 2024
Employees
61
+3.4% vs 2024
Profit before tax
-£61M
+9.8% vs 2024
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Negative shareholders' funds
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2025-04-30
| Metric | Trend | 2024-04-30 | 2025-04-30 | Δ vs prior |
|---|---|---|---|---|
| Turnover | — | — | — | |
| Operating profit | -£67,819,741 | -£63,203,011 | +6.8% | |
| Profit before tax | -£67,695,110 | -£61,066,694 | +9.8% | |
| Net profit | -£60,965,848 | -£61,696,872 | -1.2% | |
| Cash | £9,921,199 | £61,152,922 | +516.4% | |
| Total assets less current liabilities | -£994,004 | £46,565,907 | +4,784.7% | |
| Net assets | -£994,004 | -£30,808,971 | -2,999.5% | |
| Equity | -£994,004 | -£30,808,971 | -2,999.5% | |
| Average employees | 59 | 61 | +3.4% | |
| Wages | £6,254,057 | £7,346,280 | +17.5% | |
| Directors' remuneration | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-04-30 | 2025-04-30 |
|---|---|---|---|
| Return on capital employed | — | -135.7% | |
| Gearing (liabilities / total assets) | 104.7% | 140.4% | |
| Current ratio | 0.89x | 2.53x | |
| Interest cover | — | -14.00x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- KALVISTA PHARMACEUTICALS LIMITED 2011-05-06 → present
- KALVISTA LIMITED 2011-04-28 → 2011-05-06
- NEWINCCO 1089 LIMITED 2011-02-25 → 2011-04-28
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors have received assurances that adequate financial support from the Parent Company will be available to enable the Company to fund operations. The group forecasts indicate sufficient cash resources to support the ongoing expenditure for at least the next twelve months from the date of approval of the audited financial statements.”
Significant events
- “In November 2024, KalVista entered into a purchase and sale agreement under which it received an upfront payment of $100.0 million in exchange for tiered payments based on future global net sales of Sebetralstat. The arrangement includes additional milestone payments contingent on sales performance.”
- “In April 2025, the Company also entered into a licensing agreement for the Japanese market, securing upfront and potential milestone payments, as well as future royalty income.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 12 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| CSC CLS (UK) LIMITED | Corporate Secretary | 2026-01-28 | — | — |
| PALLEIKO, Ben | Director | 2016-12-08 | Jul 1965 | American |
| PIEKOS, Brian | Director | 2024-11-27 | Aug 1974 | American |
Show 12 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DONNELLY, Stephen Gerard | Secretary | 2011-05-23 | 2024-11-27 |
| OLSWANG COSEC LIMITED | Corporate Secretary | 2011-02-25 | 2011-05-23 |
| ALDRICH, Richard | Director | 2015-06-29 | 2016-12-06 |
| BINGHAM, Catherine Elizabeth, Dame | Director | 2015-11-11 | 2016-06-27 |
| BOULNOIS, Graham | Director | 2011-05-23 | 2015-11-11 |
| CROCKETT, Thomas Andrew | Director | 2011-05-23 | 2024-03-07 |
| EDWARDS, Martin William | Director | 2011-05-23 | 2016-12-06 |
| MACKIE, Christopher Alan | Director | 2011-02-25 | 2011-05-23 |
| RESNICK, Joshua Benjamin, Dr | Director | 2016-06-27 | 2016-12-06 |
| SHAH, Rajeev | Director | 2015-06-29 | 2016-12-06 |
| OLSWANG DIRECTORS 1 LIMITED | Corporate Director | 2011-02-25 | 2011-05-23 |
| OLSWANG DIRECTORS 2 LIMITED | Corporate Director | 2011-02-25 | 2011-05-23 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Kalvista Pharmaceuticals Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-11-21 | Active |
Filing timeline
Last 20 of 98 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-09 | AA | accounts | Accounts with accounts type full | |
| 2026-04-28 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-02-26 | CH01 | officers | Change person director company with change date | |
| 2026-02-25 | CH01 | officers | Change person director company with change date | |
| 2026-02-25 | CH01 | officers | Change person director company with change date | |
| 2026-02-24 | CH01 | officers | Change person director company with change date | |
| 2026-02-24 | AP04 | officers | Appoint corporate secretary company with name date | |
| 2026-02-24 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-12-03 | AA01 | accounts | Change account reference date company current shortened | |
| 2025-10-31 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2025-02-25 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-12-24 | AA | accounts | Accounts with accounts type small | |
| 2024-11-27 | AP01 | officers | Appoint person director company with name date | |
| 2024-11-27 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-11-11 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2024-03-20 | TM01 | officers | Termination director company with name termination date | |
| 2024-02-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-11-28 | AA | accounts | Accounts with accounts type small | |
| 2023-02-28 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-11-07 | AA | accounts | Accounts with accounts type small |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 10
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.